Influenza A Market to Witness Robust Expansion at a CAGR of 8.5% in the United States During the Study Period (2019-2032), Assesses DelveInsight

10 Jan 2023
www.prnewswire.com
VaccineLicense out/inDrug ApprovalPhase 2
The influenza A market is expected to surge in the coming years as the emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action for the treatment of patients affected with influenza A infections. At a global level, some key players in the
influenza A market are Sanofi, AstraZeneca, GSK, and others.
LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- DelveInsight's
Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Influenza A Market Report
As per DelveInsight analysis, the influenza A market size in the US was approximately
USD 3.6 billion in 2021
According to the assessment done by DelveInsight, the total vaccinated pool of influenza A in the United States was approximately
176 million in 2021
Leading influenza A companies such as
Cidara Therapeutics, SAb Biotherapeutics, FluGenFluGen, Moderna, Vir Biotechnology, Vaxart, Genentech, Roche, BioCryst Pharmaceuticals, Sanofi, AstraZeneca, Seqirus, GSK, and others are developing novel influenza A drugs that can be available in the influenza A market in the coming years
The promising influenza A therapies/vaccines in the pipeline include
CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1
, and others
The increase in influenza A market size is a direct consequence of an increase in R&D activity, increasing prevalent population, and the expected commercial success of upcoming therapies.
In
September 2022,
Cidara Therapeutics announced the initiation of its Phase IIa trial to evaluate the pre-exposure prophylactic activity of CD388 against the influenza virus
In
April 2021,
Cidara Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement with
Janssen Pharmaceuticals, to develop and commercialize CidaraCidara's Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza
Discover which therapies are expected to grab the major influenza A market share @
Influenza A Market Report
Influenza A Overview
Influenza is an acute viral respiratory disease caused by respiratory tract infection with influenza viruses (seasonal influenza A and B viruses) that circulate worldwide. Unlike annual seasonal epidemics, sporadic pandemic outbreaks are caused by zoonotic influenza A virus strains.
Symptoms of influenza virus infection range from mild upper respiratory disease characterized by fever, sore throat, runny nose, cough, headache, muscle pain, and fatigue to severe and, in some cases, lethal pneumonia caused by influenza virus or secondary bacterial infection of the lower respiratory tract.
The clinical presentation and epidemiological likelihood of infection are used to make an influenza A diagnosis. Nonspecific influenza A symptoms, such as fever, chills, frank shaking, headaches, myalgia, malaise, and anorexia, predominate at first. These influenza A symptoms usually appear suddenly, and respiratory symptoms, such as a dry cough, sore or dry throat, nasal obstruction, and discharge, are also present.
Influenza A Epidemiology Segmentation
DelveInsight estimates that the total influenza A positive cases in the United States comprised approximately
42.5K cases in 2021 and are projected to increase during the study period.
In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed
19, 7,405, and
35,156 cases in 2021.
The
influenza A market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Vaccinated Pool of Influenza A
Influenza A Positive Cases
Strain-specific Cases of Influenza A (2019–2022)
Download the report to understand which factors are driving influenza A epidemiology trends @
Influenza A Epidemiological Insights
Influenza A Treatment Market
Early antiviral intervention can benefit public health by improving clinical outcomes for patients at high risk of influenza-related complications, as well as potentially saving patients and the healthcare system money.
MedImmune introduced the first licensed live attenuated influenza virus vaccine (LAIV) in the United States in 2003. This vaccine is based on the influenza A/Ann Arbor/6/1960 backbones. LAIVs appear to be more effective than inactivated influenza virus preparations at inducing mucosal and broadly protective immune responses in infants and children. However, studies in the United States with LAIVs have revealed poor efficacy against influenza A H1N1 component1.
Another breakthrough for influenza vaccines occurred in 2013 when the FDA approved
FLUZONE QUADRIVALENT, a product made entirely of recombinant DNA technologies. Antiviral drugs, in conjunction with vaccines, are critical in preventing and treating influenza virus infection and disease. During a typical influenza season, antiviral drugs are primarily used to treat severely ill patients, particularly those with a compromised immune system.
TAMIFLU, RELENZA, and RAPIVAB are approved therapies that work by mimicking sialic acid binding in the active site of NA on influenza A and B viruses.
To know more about influenza A guidelines, visit @
Influenza A Treatment Options
Influenza A Pipeline Therapies/Vaccines and Key Companies
M2SR: FluGen
mRNA-1010: Moderna
VXA-A1.1: Vaxart
Learn more about the FDA-approved influenza A drugs @
Drugs for Influenza A Treatment
Influenza A Market Dynamics
The dynamics of the influenza A market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Moreover, the presence of a
large number of manufacturers contributes to the influenza A market growth. Furthermore, key players are heavily
investing in research activities to broaden the therapeutic application of treatment drugs, thereby expanding the scope and opportunities for the treatment, thereby boosting the influenza A market growth.
However, certain factors act as barriers and affect the influenza A market growth. The
inadequate epidemiological data availability of patient care reference centers is among the prominent factors hampering the growth of the influenza A market. Moreover, the global influenza A market is fragmented, owing to the
presence of several major players. Furthermore,
payers and insurance companies will attempt to limit the use of drugs with
mediocre efficacy but high prices, thus leading to a dip in the growth of the influenza A market. Hence, all these factors mentioned above are likely to impede the influenza A market growth in the future.
Scope of the
Market Report
Therapeutic Assessment: Influenza A current marketed and emerging therapies
Market Dynamics: Influenza A market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Influenza A Market Access and Reimbursement
Discover more about influenza A drugs in development @
Influenza A Clinical Trials
Table of Contents
Related Reports
Influenza A Epidemiology Forecast
Influenza A Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted influenza A epidemiology in the 7MM, i.e., the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Influenza A Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A infections companies, including
Influenza B Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza B infections companies, including
Influenza Pipeline
Influenza Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including
Seasonal Influenza Market
Seasonal Influenza Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key seasonal influenza companies, including
Influenza A Virus H5N1 Subtype Pipeline
Influenza A Virus H5N1 Subtype Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A virus H5N1 subtype companies, including
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Additionally, get in touch with our business executive to explore @
Healthcare Due Diligence Services
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.